The PDGFR tyrosine kinase inhibitor imatinib has been shown to inhibit the viability of NKTCL cells and induce an arrest of cell cycle at G0/G1 stage [100]. The gene discussed is PDGFRB; the disease is extranodal nasal NK/T cell lymphoma.